Latest News

  • Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® Program Read More
  • Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities Read More
  • New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II Read More
  • Alkermes to Take Part in 41st Annual Goldman Sachs Global Healthcare Conference Read More

Investors

ALKS investor relations
Learn more Learn More

Pipeline

patient focused CNS disorder treatments
See Our Approach See Our Approach

Response to Current Events

Response to Current Events
Response to Current Events Read Our Statement